J Korean Med Sci.  2008 Dec;23(6):982-987. 10.3346/jkms.2008.23.6.982.

Imipenem-Resistant Pseudomonas aeruginosa : Risk Factors for Nosocomial Infections

• Onguru P
• Erbay A
• Bodur H
• Baran G
• Akinci E
• Balaban N
• Cevik MA

• KMID: 1107521
• DOI: http://doi.org/10.3346/jkms.2008.23.6.982

Abstract

The aim of this study was to determine the risk factors for nosocomial infections of imipenem-resistant Pseudomonas aeruginosa (IRPA). A prospective case-control study was performed at a tertiary care hospital in Ankara from January to December 2004. The patients with nosocomial P. aeruginosa infection were included in the study. The features of the patients with IRPA infections were compared to those with imipenem-sensitive P. aeruginosa (ISPA) infections. Only the first isolation of P. aeruginosa was considered. Nosocomial infections were defined according to Center for Disease Control (CDC) criteria. IRPA was isolated from 75 (44.1%) patients, and ISPA was isolated from 95 (55.9%) patients during the study period. IRPA were most frequently isolated from endotracheal aspirate (19%) cultures (p= 0.048), whereas ISPA were most frequently isolated from urine (28%) cultures (p= 0.023). In multivariate analysis, a longer duration of hospital stay until P. aeruginosa isolation (odds ratio [OR], 1.027; 95% confidence interval [CI], 1.002-1.054, p=0.034), arterial catheter administration (OR, 2.508; 95% CI, 1.062-5.920, p=0.036), vancomycin (OR, 2.882; 95% CI, 1.130-7.349, p=0.027), piperacillin-tazobactam (OR, 6.425; 95% CI, 2.187-18.875, p=0.001), and imipenem (OR, 3.580; 95% CI, 1.252- 10.245, p=0.017) treatment within the 14 days before isolation of IRPA were independently associated with imipenem resistance. It was concluded that treatment with imipenem, vancomycin and piperacillin-tazobactam were major risk factors for IRPA infections in hospitalized patients. The nosocomial occurrence of IRPA was also strongly related to the duration of hospital stay, arterial catheter administration.

Keyword

Pseudomonas; Cross Infection; Risk Factors; Imipenem Resistance

MeSH Terms

Adult
Aged
Anti-Bacterial Agents/*pharmacology/therapeutic use
Case-Control Studies
Cross Infection/drug therapy/epidemiology/*microbiology
Drug Resistance, Multiple, Bacterial
Female
Humans
Imipenem/*pharmacology/therapeutic use
Length of Stay
Male
Microbial Sensitivity Tests
Middle Aged
Multivariate Analysis
Penicillanic Acid/analogs & derivatives/pharmacology/therapeutic use
Piperacillin/pharmacology/therapeutic use
Prospective Studies
Pseudomonas Infections/drug therapy/epidemiology/*microbiology
Pseudomonas aeruginosa/drug effects/*isolation & purification
Risk Factors
Vancomycin/pharmacology/therapeutic use

Reference

1. Fluit AC, Verhoef J, Schmitz FJ. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY Participants. Eur J Clin Microbiol Infect Dis. 2000. 19:370–374.

2. Quinn JP. Imipenem resistance among gram-negative bacilli. Eur J Clin Microbiol Infect Dis. 1994. 13:203–204.

3. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999. 43:1379–1382.

4. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999. 29:245–252.

5. Deshpande LM, Fritsche TR, Jones RN. Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2004. 49:231–236.

6. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect. 2005. 59:96–101.

7. King A, Shannon K, Phillips I. Resistance to imipenem in Pseudomonas aeruginosa. J Antimicrob Chemother. 1995. 36:1037–1041.

8. Akinci E, Colpan A, Bodur H, Balaban N, Erbay A. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections. J Hosp Infect. 2005. 59:317–323.

9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988. 16:128–140.

10. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis. 2000. 30:454–460.

11. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother. 1998. 42:1762–1770.

12. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis. 2002. 34:340–345.

13. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 1997. 25:1094–1098.

14. Yapar N, Erdenizmenli M, Gülay Z, Küçükgüven Biçmen M, Yüce A, Yuluğ N. Pseudomonas aeuroginosa, Acinetobacter ve Staphylococcus Turlerinin Antibiyotik Direnci. Turk J Infect. 2000. 14:507–509.

15. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004. 32:470–485.

16. Gaynes RP, Culver DH. Resistance to imipenem among selected Gram-negative bacilli in the United States. Infect Control Hosp Epidemiol. 1992. 13:10–14.

17. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006. 27:893–900.

18. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006. 50:43–48.

19. Fortaleza CM, Freire MP, Filho Dde C, de Carvalho Ramos M. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol. 2006. 27:901–906.

20. Erol S, Altoparlak U, Akcay MN, Celebi F, Parlak M. Changes of microbial flora and wound colonization in burned patients. Burns. 2004. 30:357–361.

21. Satake S, Yoneyama H, Nakae T. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 1991. 28:199–207.